Related references
Note: Only part of the references are listed.Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
Francesca Bonifazi et al.
BONE MARROW TRANSPLANTATION (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Arnon Nagler et al.
CLINICAL CANCER RESEARCH (2022)
In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
Matthias Stelljes et al.
BLOOD (2022)
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
Kordelia Barbullushi et al.
BLOOD (2022)
Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
Dietger Niederwieser et al.
BLOOD (2022)
Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology
Ryan J. Stubbins et al.
CURRENT ONCOLOGY (2022)
Mayo Clinic experience with 1123 adults with acute myeloid leukemia
Kebede H. Begna et al.
BLOOD CANCER JOURNAL (2021)
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Martin Carre et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT
Giorgia Battipaglia et al.
BONE MARROW TRANSPLANTATION (2019)
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
Celalettin Ustun et al.
LEUKEMIA (2019)
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Eolia Brissot et al.
HAEMATOLOGICA (2019)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity
Mary Eapen et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Eolia Brissot et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years
Sarah A. Wall et al.
BLOOD REVIEWS (2017)
Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome
D. Modi et al.
BONE MARROW TRANSPLANTATION (2017)
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation
Bartlomiej M. Getta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Allogeneic Transplantation for Advanced Acute Myeloid Leukemia: The Value of Complete Remission
Daniel J. Weisdorf et al.
CANCER (2017)
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission
A. Ruggeri et al.
BONE MARROW TRANSPLANTATION (2016)
Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually
J. R. Passweg et al.
BONE MARROW TRANSPLANTATION (2016)
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
Philippe Armand et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
H Bertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial
AK Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia:: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)
M Michallet et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
